CELEBRATING 10 YEARS OF THE COMMON DRUG REVIEW 2003–2013

WE SUPPORT CANADIANS

19 publicly funded drug plans serving 11.3 million people

PAN-CANADIAN* PROCESS:
Conducting reviews of the clinical, cost-effectiveness, and patient group input for drugs
Providing evidence-based formulary listing recommendations

WE ASSESS EVIDENCE

70 pharmaceutical manufacturers have filed submissions since 2003
75 patient groups have provided input since 2010
89,680 published articles have been reviewed since 2003
236 recommendations by CDEC since 2003

WE PROVIDE VALUE

90% Relevance 90% of the time, participating drug plans agree with CDR recommendations, increasing coverage consistency for Canadians

TIMELINESS Reduced time to listing by a median of 67 days**

TRANSPARENCY Recommendations and reasons are always shared publicly

WE CONTINUE TO EVOLVE

'03 Common Drug Review open for business
'06 Public members added to CEDAC with full voting rights
'10 Patient groups begin to provide input
'11 CDEC formed to provide formulary and optimal use recommendations
'13 Common Drug Review continues to evolve to bring value to health care decision-makers

The Canadian Agency for Drugs and Technologies in Health (CADTH) is an independent, not-for-profit organization funded by the federal, provincial and territorial governments of Canada. The statements, conclusions, and views expressed herein do not necessarily represent the view of Health Canada or any provincial, territorial or federal government.

* Includes all publicly funded drug plans except Quebec.
† The pan-Canadian Oncology Drug Review (pCODR) reviews cancer drugs. CADTH is a pCODR partner.

** Derived from IMS-Brogan Provincial Reimbursement Advisor

As at March 2013.